WangH, PatiS, Pozzo-MillerL, DoeringLC: Targeted pharmacological treatment of autism spectrum disorders: Fragile X and Rett syndromes. Front Cell Neurosci, 26; 9:55, 2015.
2.
LiW, Pozzo-MillerL: BDNF deregulation in Rett syndrome. Neuropharmacology, 76Pt C:737–746, 2014.
3.
DengV, MatagneV, BanineF, et al.: FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. Hum Mol Genet, 16:640–650, 2007.
4.
TsaiSJ: Lithium and antidepressants: Potential agents for the treatment of Rett syndrome. Med Hypotheses, 67:626–629, 2006.
5.
DwivediT, ZhangH: Lithium-induced neuroprotection is associated with epigenetic modification of specific BDNF gene promoter and altered expression of apoptotic-regulatory proteins. Front Neurosci, 14; 8:457, 2015.
